CA
NZ
UK
AU
IND
US
• The company plans to raise $100 million in common stock and $300 million in convertible senior notes due 2031.
• The company priced a registered direct offering of 750,000 shares at $1.00 per share.
• Reports indicate KKR and Sixth Street Partners have agreed to a $1 billion preferred equity financing.
• Third-quarter fiscal 2026 revenue reached $1.43 billion, up 11% year over year on a headline basis.
• The FDA approved Lumvoa (veligrotug) under priority review for both active and chronic thyroid eye disease.
• The company was added to multiple Russell Growth indices, including Russell 2000 and Russell 3000E Growth.
• BSX shares rose 0.28% pre-market to $42.80, following a 1.84% decline that pushed shares to a 52-week low of $42.25.
• The $1.6 billion transaction combined equity and convertible note placements.
• The company appointed a new independent director effective June 30, 2026.
• The fund issued 1,346,668 shares at a weighted average price of $25.17 per share.
Please wait processing your request...